Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
90 hedge funds and large institutions have $166M invested in Syros Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 22 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 31
10% less funds holding
Funds holding: 100 → 90 (-10)
26% less capital invested
Capital invested by funds: $223M → $166M (-$57.1M)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
66% less call options, than puts
Call options by funds: $85K | Put options by funds: $249K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$4.05M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$1.94M |
| 3 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
+$1.85M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$688K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$668K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$907K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$820K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$792K |
| 4 |
Morgan Stanley
New York
|
-$646K |
| 5 |
BlackRock
New York
|
-$492K |
SYRS Hedge Fund Activity: Q4 2021 in Review
90 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2021, worth a combined $166M — down 26% from $223M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SYRS and 12 opened new positions — a net loss of 10 holders — while 31 trimmed existing stakes and 31 added.
The largest buyer was Artal Group, adding an estimated $4.05M. The largest seller was Millennium Management, cutting an estimated $907K.
- 90 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2021, down from 100 in Q3 2021.
- Funds reported $166M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 26% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 22 closed out, a net change of -10 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Artal Group, an estimated $4.05M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $907K sold.
Based on aggregated 13F filings for Q4 2021.